Acromegaly treatment and bone: a bidirectional relationship

Area of Science:

• Endocrinology
• Bone Metabolism
• Pharmacology

Background:

• Acromegaly results from excess growth hormone (GH) and insulin-like growth factor I (IGF-I) secretion.
• Excess GH and IGF-I lead to systemic complications, including increased risk of fragility vertebral fractures (VFs).
• Long-term exposure to high GH/IGF-I levels is a known risk factor for fractures in acromegaly.

Purpose of the Study:

• To review the incidence of vertebral fractures (VFs) in acromegaly patients treated with GH/IGF-I-lowering drugs.
• To explore the potential effects of these treatments on bone metabolism.
• To summarize preclinical data on molecular interactions between GH/IGF-I-lowering drugs and bone.

Main Methods:

• Literature review of studies on vertebral fracture incidence in acromegaly.
• Analysis of data on the impact of GH/IGF-I-lowering drugs on bone metabolism.
• Inclusion of preclinical data on molecular pathways.

Main Results:

• First- and second-generation somatostatin receptor ligands (SRLs) have shown reduced incidence of vertebral fractures (i-VFs).
• Direct effects of SRLs on bone metabolism are not yet fully reported.
• Preclinical data may elucidate molecular mechanisms linking these drugs to bone health.

Conclusions:

• GH/IGF-I-lowering drugs, particularly SRLs, appear to reduce vertebral fracture incidence in acromegaly.
• Further research is needed to understand the direct impact of these therapies on bone metabolism and related molecular pathways.